

Lucia Moiola

List of Publications by Citations

Source: <https://exaly.com/author-pdf/628578/lucia-moiola-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

3,579
citations

34
h-index

54
g-index

137
ext. papers

4,301
ext. citations

5.6
avg, IF

4.9
L-index

#	Paper	IF	Citations
131	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 374, 1503-11	40	475
130	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 780-789	9.4	189
129	IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. <i>European Journal of Immunology</i> , 1998 , 28, 2487-97	6.1	99
128	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 420-4	5	90
127	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. <i>Neuroscience Letters</i> , 2012 , 508, 4-8	3.3	79
126	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1533-8	5	79
125	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , 2014 , 83, 1432-8	6.5	78
124	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1074-83	5	72
123	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124	3.1	72
122	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165	3.1	66
121	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 329-34	5	65
120	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 511-9	5	64
119	Functional and structural connectivity of the motor network in pediatric and adult-onset relapsing-remitting multiple sclerosis. <i>Radiology</i> , 2010 , 254, 541-50	20.5	63
118	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1076-83	5	61
117	Natalizumab in the pediatric MS population: results of the Italian registry. <i>BMC Neurology</i> , 2015 , 15, 174	3.1	58
116	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009 , 30, 193-9	3.5	58
115	Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients?. <i>Human Brain Mapping</i> , 2009 , 30, 2844-51	5.9	57

114	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831	6.5	54
113	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1106-12	5	50
112	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , 2007 , 28, 127-32	3.5	49
111	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , 2018 , 90, e832-e839	6.5	48
110	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50	5.5	48
109	Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1342-7	5	47
108	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1315-26	5	46
107	Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. <i>Journal of Clinical Investigation</i> , 1994 , 93, 1020-8	15.9	41
106	Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. <i>Neurology</i> , 2014 , 82, 1314-21	6.5	40
105	Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. <i>CNS Drugs</i> , 2017 , 31, 33-50	6.7	39
104	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1506-1508	5	36
103	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, 467-70	3.5	36
102	Marchiafava-Bignami disease: longitudinal MR imaging and MR spectroscopy study. <i>American Journal of Neuroradiology</i> , 2003 , 24, 249-53	4.4	36
101	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1738-1744	5.3	36
100	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016 , 263, 1727-35	5.5	35
99	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014 , 75, 447-53	9.4	35
98	Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. <i>PLoS ONE</i> , 2016 , 11, e0168376	3.7	35
97	Intranetwork and internetwork functional connectivity abnormalities in pediatric multiple sclerosis. <i>Human Brain Mapping</i> , 2014 , 35, 4180-92	5.9	34

96	COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. <i>European Journal of Neurology</i> , 2021 , 28, 3375-3383	6	33
95	To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 697-705	9.4	30
94	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 520-6	4	30
93	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. <i>Neurology</i> , 2019 , 92, e733-e741	6.5	30
92	Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. <i>Neurological Sciences</i> , 2016 , 37, 235-42	3.5	28
91	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16	3.5	28
90	No evidence of disease activity is associated with reduced rate of axonal retinal atrophy in MS. <i>Neurology</i> , 2017 , 89, 2469-2475	6.5	27
89	Gamma interferon activates a previously undescribed Ca ²⁺ influx in T lymphocytes from patients with multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 4825-9	11.5	26
88	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 347-359	5	24
87	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018 , 265, 2851-2860	5.5	24
86	T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 1993 , 681, 198-218	6.5	23
85	Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor. <i>Journal of Clinical Investigation</i> , 1992 , 90, 1558-67	15.9	23
84	Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. <i>Annals of Neurology</i> , 2019 , 85, 606-610	9.4	23
83	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114	3.1	22
82	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1490-9	5	22
81	Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis. <i>Pharmacogenomics Journal</i> , 2017 , 17, 84-91	3.5	21
80	Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 956-9	5	21
79	Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. <i>Journal of Neurology</i> , 2021 , 1	5.5	21

78	Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1197-1206	5	21
77	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035318	5	21
76	Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 628-40	5	20
75	Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice. <i>Journal of the Neurological Sciences</i> , 2017 , 383, 166-168	3.2	20
74	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 399-407	5	20
73	Dysregulation of MS risk genes and pathways at distinct stages of disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e337	9.1	19
72	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1741-1749	5	19
71	In vivo structural and functional assessment of optic nerve damage in neuromyelitis optica spectrum disorders and multiple sclerosis. <i>Scientific Reports</i> , 2019 , 9, 10371	4.9	19
70	Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 702-7	5	19
69	Myeloid cells as target of fingolimod action in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e157	9.1	18
68	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. <i>Neurological Sciences</i> , 2013 , 34, 1633-7	3.5	17
67	Brain macro- and microscopic damage in patients with paediatric MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1357-62	5.5	17
66	Practice of yoga may cause damage of both sciatic nerves: a case report. <i>Neurological Sciences</i> , 2013 , 34, 393-6	3.5	16
65	Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. <i>Journal of the Neurological Sciences</i> , 2020 , 409, 116603	3.2	16
64	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020 , 17, 208-217	6.4	16
63	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 331-346	5	16
62	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 454-461	3.8	15
61	Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study. <i>Neurology</i> , 2019 , 92, e1709-e1723	6.5	15

60	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 167-174	5	14
59	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e129	9.1	14
58	Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 403-405	4	14
57	Abnormal cerebellar functional MRI connectivity in patients with paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 292-301	5	13
56	Validation of 1-year predictive score of long-term response to interferon- β in everyday clinical practice multiple sclerosis patients. <i>European Journal of Neurology</i> , 2015 , 22, 973-80	6	13
55	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. <i>Journal of Neuroimmunology</i> , 2015 , 289, 62-7	3.5	13
54	Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis. <i>Multiple Sclerosis International</i> , 2016 , 2016, 2303857	1.1	13
53	Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020 , 33, 286-294	7.1	12
52	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 799-805	8	11
51	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012 , 530, 155-60	3.3	11
50	Interferon-gamma induces T lymphocyte proliferation in multiple sclerosis via a Ca(2+)-dependent mechanism. <i>Journal of Neuroimmunology</i> , 1995 , 62, 169-76	3.5	11
49	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 802-11	5	10
48	Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?. <i>Journal of the Neurological Sciences</i> , 2017 , 378, 233-237	3.2	9
47	MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. <i>Neurology</i> , 2017 , 89, 1265-1273	6.5	9
46	In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. <i>Brain</i> , 2021 , 144, 186-197	11.2	9
45	Caesarean section and infant formula feeding are associated with an earlier age of onset of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 75-77	4	8
44	Recurrence of disease activity after repeated Natalizumab withdrawals. <i>Neurological Sciences</i> , 2015 , 36, 465-7	3.5	8
43	Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. <i>Journal of Neurology</i> , 2018 , 265, 896-905	5.5	8

42	Resting state network functional connectivity abnormalities in systemic lupus erythematosus: correlations with neuropsychiatric impairment. <i>Molecular Psychiatry</i> , 2021 , 26, 3634-3645	15.1	8
41	MGAT5 and disease severity in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011 , 230, 143-7	3.5	7
40	Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e591	9.1	6
39	Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 1990 , 30, 129-34	3.5	6
38	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	6
37	Inferring Multiple Sclerosis Stages from the Blood Transcriptome via Machine Learning. <i>Cell Reports Medicine</i> , 2020 , 1, 100053	18	6
36	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1520-1532	5	6
35	COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. <i>Journal of Neurology</i> , 2021 , 268, 2697-2699	5.5	6
34	Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. <i>Neurological Sciences</i> , 2018 , 39, 1467-1470	3.5	6
33	Loss of Circulating CD8+ CD161 T Cells in Primary Progressive Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2019 , 10, 1922	8.4	5
32	Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1752-1761	2.3	5
31	Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two cases. <i>Neurological Sciences</i> , 2017 , 38, 361-364	3.5	5
30	The Communication of Multiple Sclerosis Diagnosis: The PatientsTPerspective. <i>Multiple Sclerosis International</i> , 2015 , 2015, 353828	1.1	5
29	Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. <i>Autoimmunity</i> , 2020 , 53, 21-27	3	5
28	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	4
27	Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia. <i>Current Rheumatology Reports</i> , 2021 , 23, 52	4.9	4
26	Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. <i>Expert Review of Neurotherapeutics</i> , 2021 , 21, 21-34	4.3	4
25	The still under-investigated role of cognitive deficits in PML diagnosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017 , 2,	0	3

24	Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes. <i>Brain</i> , 2021 , 144, 848-862	11.2	3
23	Early Predictors of 9-Year Disability in Pediatric Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 1011-1022	10.2	3
22	Moyamoya disease mimicking the first attack of multiple sclerosis. <i>Journal of Neurology</i> , 2017 , 264, 1005-1007	5.1	2
21	Cognitive reserve is a determinant of social and occupational attainment in patients with pediatric and adult onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102145	4	2
20	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. <i>Acta Neurologica Scandinavica</i> , 2018 , 138, 447-453	3.8	2
19	Subacute visual loss and bilateral fixed mydriasis: an atypical case of giant cell arteritis. <i>Neurological Sciences</i> , 2014 , 35, 1309-10	3.5	2
18	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211023365	5	2
17	Dynamic pattern of clinical and MRI findings in a tumefactive demyelinating lesion: A case report. <i>Journal of the Neurological Sciences</i> , 2016 , 361, 184-6	3.2	2
16	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study. <i>Neurotherapeutics</i> , 2021 , 18, 878-888	6.4	2
15	Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer. <i>Journal of Neurology</i> , 2019 , 266, 3163-3166	5.5	1
14	Allogeneic Hematopoietic Stem Cell Transplantation For Severe Neuromyelitis Optica. <i>Blood</i> , 2013 , 122, 5539-5539	2.2	1
13	Necrotic-hemorrhagic myelitis: A rare malignant variant of parainfectious acute disseminated encephalomyelitis in childhood. <i>Journal of the Neurological Sciences</i> , 2018 , 384, 58-60	3.2	1
12	Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1374-1383	5	1
11	Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2020 , 418, 117104	3.2	1
10	Neuromyelitis optica and myotonic dystrophy type 2: a rare association with diagnostic implications. <i>Journal of Neurology</i> , 2020 , 267, 2744-2746	5.5	1
9	Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports. <i>Neurological Sciences</i> , 2021 , 42, 9-13	3.5	1
8	Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?. <i>Journal of Neurology</i> , 2021 , 268, 3975-3979	5.5	1
7	Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab. <i>Viruses</i> , 2016 , 8,	6.2	1

6	Progressive ataxia in a natalizumab-treated multiple sclerosis patient: the dark side of JC virus infection. <i>European Journal of Neurology</i> , 2016 , 23, e39-40	6	1
5	Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 57-59	4	1
4	HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis.. <i>Neurological Sciences</i> , 2022 , 43, 2095	3.5	0
3	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , 2022 , 98, e1626-e1636	6.5	0
2	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β 1a in multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101952	4	
1	Successful treatment of HIV-associated tumefactive demyelinating lesions with corticosteroids and cyclophosphamide: a case report. <i>Journal of Neurology</i> , 2020 , 267, 3773-3775	5.5	